Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

KLP Kapitalforvaltning AS purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the ...

CRISPR Therapeutics (NASDAQ:CRSP) shares snapped six straight sessions of losses on Wednesday, as the stock closed 3% to $34.18. The Switzerland-based biotech company lost about 19% in the preceding ...

Therefore, it is wise to be aware of the facts that can impact the stock's prospects. Among them are CRISPR Therapeutics (NASDAQ: CRSP) and Merck (NYSE: MRK), two companies that develop innovative ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report released on ...

Stocks: Real-time U.S. stock quotes reflect trades reported through ... Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange ...

If an investor was to purchase shares of CRSP stock at the current price level of $41.15/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

Therefore, it is wise to be aware of the facts that can impact the stock's prospects. Among them are CRISPR Therapeutics (NASDAQ: CRSP) and Merck (NYSE: MRK), two companies that develop innovative ...

Stocks: Real-time U.S. stock quotes reflect trades reported through ... Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange ...